Spect
Value-based retinal screening in primary care to prevent blindness.
What they do
Retinal disease screening for diabetic and other at-risk patients is costly, inefficient, and limited by the need for ophthalmologists to manually assess fundus images, leading to preventable blindness.
Spect provides value-based retinal screening in primary care using technology to enable scalable detection of conditions like diabetic retinopathy and glaucoma.
Primary care clinics and health systems screening diabetic and other at-risk patients use it to identify vision disease earlier.
Founders
After undergrad and a Master's at Stanford University, where I completed the Biodesign program, I started my career in healthcare venture capital. Afterward, I went to medical school at UT Southwestern in Texas and did my residency training in Ophthalmology at the National Eye Institute (NIH), University of Chicago, Geisinger, and Stanford Medicine. I’ve mentored several and started three companies, including Spect.
Company timeline
- Founded2017
- YC batchSummer 2017
- StatusInactive
- Team size7 people
- LocationPalo Alto, CA, USA; Remote
Similar startups
